POXEL : News à l'instant | page 2

remrub

30 juin 2025 •18:35

Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update
Download as PDF
June 30, 2025

LYON, France--(BUSINESS WIRE)-- Regulatory News:

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including Metabolic dysfunction-Associated SteatoHepatitis (MASH) and rare metabolic disorders, today announces the postponement of its 2025 Annual General Meeting, which is intended to approve the financial statements for the year ended December 31, 2024, and provides a corporate update.

By order dated June 24, 2025, the President of the Lyon Court for Economic Activities, granted the Company’s request to postpone Poxel’s 2025 Annual General Meeting by extending the deadline for holding it until December 31, 2025, at the latest.

Initially scheduled for June 26, 2025, the Annual General Meeting has been postponed to a later date due to the delay in the approval of its statutory and consolidated financial statements for the fiscal year ended December 31, 2024.

As announced on April 16, 2025, due to the potential impact of ongoing negotiations on its financial statements with the Company’s financial creditors and with potential partners for the development of its product pipeline, Poxel postponed the closing and publication of its 2024 annual results.

The holding of the Annual General Meeting remains subject to the approval of the financial statements for the year ended December 31, 2024, by the Board of Directors.

Pending the outcome of ongoing negotiations, the Company currently estimates that its cash runway extends though the course of July 2025.

Poxel will update the market and its shareholders on its revised 2025 financial calendar as soon as possible, including the date of its next General Meeting.